Teledyne agrees to acquire Varex Imaging for $1.1bn
Teledyne Technologies agreed to buy Varex Imaging in a cash deal valued at nearly $1.1 billion. Teledyne will pay $18.90 per Varex share, including equity awards and net debt as of April 3, 2026, subject to closing conditions. Completion is targeted for early 2027 after regulatory and stockholder approvals.
How this was made
The 30-second read
Why it matters
The definitive agreement with a stated per-share price and early 2027 target creates tradable catalysts for both takeover certainty and M&A execution risk.
Market read
Definitive M&A terms and board approvals are immediate drivers for takeover pricing, deal spreads, and expectations for regulatory approval timelines.
What to watch
The article does not specify funding structure for TDY or detailed regulatory pathways; those missing details can drive deal-spread repricing before closing.
Background
Teledyne and Varex serve related OEM customers with complementary X-ray technologies, and the deal is positioned as low-overlap integration.
Ticker impact
Teledyne agreed to buy Varex Imaging for nearly $1.1bn in a cash deal at $18.90 per share, targeting early 2027 close.
Likely supportive for TDY on deal premium optics, with volatility around regulatory/financing details into early 2027.
The article discloses definitive agreement, per-share price, and early 2027 target, which markets typically price quickly; however, regulatory and closing conditions remain unresolved.
Varex Imaging entered a definitive agreement to be acquired by Teledyne for $18.90 per share in a cash transaction valued near $1.1bn.
Supportive bias while the deal is intact, with downside risk if approvals or closing conditions deteriorate.
The article provides the definitive per-share consideration, board approvals, and early 2027 completion target, which are key drivers for takeover spreads and deal certainty.
Market effects
Could signal consolidation in X-ray sources and medical imaging software, potentially affecting competitive positioning and customer procurement decisions.
Varex’s global footprint (Asia, Europe, North America) may shift near-term supply and integration planning across regions.
Cross-border medical imaging supply chain and regulatory review processes may influence timelines for similar med-tech M&A activity.
Counterpoint
Premiums can compress if regulatory scrutiny or financing assumptions change, so the stock may not track the headline premium through the entire approval window.
Key entities
- acquirerTeledyne Technologies
Agreed to purchase Varex Imaging for nearly $1.1bn in cash at $18.90 per share.
- targetVarex Imaging
Agreed to be acquired; provides X-ray sources and imaging software for medical diagnostic imaging.
- executiveSunny Sanyal
Varex CEO and director quoted on the strategic rationale and premium for shareholders.
- executiveRobert Mehrabian
Teledyne executive chairman quoted on complementary product fit and minimal overlap.
